Literature DB >> 25019313

N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.

Marian M J H P Willems1, Gijs G Zom, Selina Khan, Nico Meeuwenoord, Cornelis J M Melief, Mario van der Stelt, Herman S Overkleeft, Jeroen D C Codée, Gijsbert A van der Marel, Ferry Ossendorp, Dmitri V Filippov.   

Abstract

New analogues (UPam) of triacylated lipopeptide Pam3CysSK4, a popular agonist of Toll-like receptor 2 (TLR2), were designed making use of the cocrystal structure of a TLR2 heterodimer (with TLR1) with Pam3CysSK4. Twenty-two UPam derivatives that feature an N-tetradecylcarbamyl chain to mimic the native N-palmitoyl moiety and various small amino acids residues at the penultimate N-terminal position were prepared via solid-phase synthesis. In vitro evaluation of immunostimulatory properties revealed new potent TLR2 ligands.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25019313     DOI： 10.1021/jm500722p

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

2.  Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.

Authors:  Gijs G Zom; Dmitri V Filippov; Gijsbert A van der Marel; Hermen S Overkleeft; Cornelis J Melief; Ferry Ossendorp
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

3.  Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.

Authors:  Frank M Speetjens; Marij J P Welters; Marije Slingerland; Mariette I E van Poelgeest; Peggy J de Vos van Steenwijk; Inge Roozen; Sanne Boekestijn; Nikki M Loof; Gijs G Zom; A Rob P M Valentijn; Willem-Jan Krebber; Nico J Meeuwenoord; Catharina A H Janssen; Cornelis J M Melief; Gijs A van der Marel; Dmitri V Filippov; Sjoerd H van der Burg; Hans Gelderblom; Ferry Ossendorp
Journal:  J Immunother Cancer       Date:  2022-10       Impact factor: 12.469

4.  The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells.

Authors:  Xueheng Guo; Ning Wu; Yingli Shang; Xin Liu; Tao Wu; Yifan Zhou; Xin Liu; Jiaoyan Huang; Xuebin Liao; Li Wu
Journal:  Front Immunol       Date:  2017-02-21       Impact factor: 7.561

5.  Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.

Authors:  Victoria A Brentville; Rachael L Metheringham; Ian Daniels; Suha Atabani; Peter Symonds; Katherine W Cook; Mireille Vankemmelbeke; Ruhul Choudhury; Poonam Vaghela; Mohamed Gijon; Ghislaine Meiners; Willem-Jan Krebber; Cornelis J M Melief; Lindy G Durrant
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

6.  Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.

Authors:  Gijs G Zom; Marian M J H P Willems; Selina Khan; Tetje C van der Sluis; Jan Willem Kleinovink; Marcel G M Camps; Gijsbert A van der Marel; Dmitri V Filippov; Cornelis J M Melief; Ferry Ossendorp
Journal:  J Immunother Cancer       Date:  2018-12-12       Impact factor: 13.751

7.  TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

Authors:  Gijs G Zom; Marij J P Welters; Nikki M Loof; Renske Goedemans; Sinéad Lougheed; Rob R P M Valentijn; Maarten L Zandvliet; Nico J Meeuwenoord; Cornelis J M Melief; Tanja D de Gruijl; Gijsbert A Van der Marel; Dmitri V Filippov; Ferry Ossendorp; Sjoerd H Van der Burg
Journal:  Oncotarget       Date:  2016-10-11

8.  Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer.

Authors:  Brett J Hos; Marcel G M Camps; Jitske van den Bulk; Elena Tondini; Thomas C van den Ende; Dina Ruano; Kees Franken; George M C Janssen; Arnoud Ru; Dmitri V Filippov; Ramon Arens; Peter A van Veelen; Noel Miranda; Ferry Ossendorp
Journal:  Oncoimmunology       Date:  2019-10-13       Impact factor: 8.110

Review 9.  Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines.

Authors:  Qingjiang Li; Zhongwu Guo
Journal:  Molecules       Date:  2018-06-29       Impact factor: 4.411

Review 10.  Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.

Authors:  Alexander J Stephens; Nicola A Burgess-Brown; Shisong Jiang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.